Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Dr. Reddy's Defeat Of FCA Case Offers 'Guidepost' For Litigation After Escobar

Dismissal of False Claims Act suit against Dr. Reddy's shows impact of US Supreme Court's Escobar decision. Government FCA pharma recoveries shot up 58% from 2015 to 2016; graphic breaks out settlements by kickback, off-label promotion and improper billing cases.

Legal Issues Policy

Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product

United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.

Deals M & A

Mogamulizumab Nips At Adcetris’s Heels In CTCL After New Results

Mogamulizumab has met its primary survival endpoint in a comparative Phase III trial in cutaneous T-cell lymphoma, positioning the Kyowa Hakko Kirin product as a potential close follower to Adcetris in the second-line setting.

Research & Development Clinical Trials

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.

Financing Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register